title: Effect of diltiazem, a moderate CYP3A inhibitor, on the pharmacokinetics of anacetrapib, a potent cholesteryl ester transfer protein inhibitor, in healthy subjects.
authors.affiliation: Merck & Co, Whitehouse Station, New Jersey, USA.
authors.forename: Amit
authors.initials: A
authors.lastname: Garg
authors.forename: Andrea
authors.initials: A
authors.lastname: Maes
authors.forename: Christy
authors.initials: C
authors.lastname: Corr
authors.forename: Bo
authors.initials: B
authors.lastname: Jin
authors.forename: Tarun
authors.initials: T
authors.lastname: Wadhwa
authors.forename: Nikhil
authors.initials: N
authors.lastname: Handa
authors.forename: Kristien
authors.initials: K
authors.lastname: Van Dyck
authors.forename: Inge
authors.initials: I
authors.lastname: De Lepeleire
authors.forename: Jinesh
authors.initials: J
authors.lastname: Shah
authors.forename: John A
authors.initials: JA
authors.lastname: Wagner
authors.forename: Rajesh
authors.initials: R
authors.lastname: Krishna
mesh_terms: D000293:Adolescent; D000328:Adult; D053480:Cholesterol Ester Transfer Proteins / Q000037:antagonists & inhibitors*; D065692:Cytochrome P-450 CYP3A Inhibitors; D003692:Delayed-Action Preparations; D004110:Diltiazem / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D004347:Drug Interactions; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006207:Half-Life; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy; D016014:Linear Models; D008297:Male; D008875:Middle Aged; D023303:Oxazolidinones / Q000009:adverse effects / Q000097:blood / Q000493:pharmacokinetics*; D055815:Young Adult
chemical_list: D053480:Cholesterol Ester Transfer Proteins; D065692:Cytochrome P-450 CYP3A Inhibitors; D003692:Delayed-Action Preparations; D004791:Enzyme Inhibitors; D023303:Oxazolidinones; D004110:Diltiazem; C530884:anacetrapib